MN-029

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2015
0120052015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Tumor vasculature is an important target in cancer treatment. Two distinct vasculartargeting therapeutic strategies are applied… (More)
Is this relevant?
2011
2011
MN-029 (denibulin HCl) is a novel vascular-disrupting agent that reversibly inhibits microtubule assembly, resulting in… (More)
  • table 1
  • table 3
  • table 2
  • table 4
  • figure 1
Is this relevant?
2009
2009
Purpose: To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, and tolerability of MN-209, a novel… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2007
Review
2007
Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and… (More)
Is this relevant?
2006
2006
3096 Background: MN-029 is a novel VDA that binds reversibly to the colchicine-binding site on tubulin and inhibits microtubule… (More)
Is this relevant?
2005
2005
BACKGROUND Vascular disrupting agents (VDAs) are designed to cause a rapid and selective shutdown of the established tumor… (More)
Is this relevant?